课题基金 / 基金详情

Calpastatin overexpression as a therapeutic approach to traumatic brain injury

Calpastatin overexpression as a therapeutic approach to traumatic brain injury
钙蛋白酶抑制素过度表达作为创伤性脑损伤的治疗方法
批准号:
8222810
负责人:
Kathleen Marie Schoch
金额:
$3.09万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-01-05 至 2013-07-04

项目摘要

项目成果

Kathleen Marie Schoch的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Traumatic brain injury (TBI) afflicts approximately 1.4 million individuals in the U.S. each year. Following TBI, a variety of cellular mediators contribute to neuronal death and dysfunction including the cysteine proteases, calpains. Prolonged activation of calpains occurs within neurons due to a rapid and sustained rise of intracellular free calcium. Although an endogenous inhibitor of calpains, calpastatin, is co- expressed, the sustained activation of these calcium-dependent proteases suggests endogenous calpastatin levels may be insufficient. The overall hypothesis of this proposal is that overexpression of calpastatin will reduce the proteolytic activity of calpains and associated neuronal death after trauma, thereby attenuating motor and cognitive deficits. Calpastatin overexpression will be induced in two ways-transgenic overexpression of human calpastatin (hCAST) (Aim 1) and calpastatin expression via lentiviral vector delivery into brain regions vulnerable to TBI (Aim 2). Aim 1 will use a novel transgenic mouse line with human calpastatin under control of the ubiquitous prion promoter. This mouse line exhibits a 9-fold greater expression of calpastatin in the cortex and hippocampus compared to wildtype mice. hCAST transgenic and wildtype littermates will be subjected to severe controlled cortical impact (CCI) injury or sham treatment. To confirm that calpastatin overexpression decreases calpain activity, cortical and hippocampal homogenates will be evaluated for calpain-mediated cytoskeletal and membrane protein breakdown via immunoblot. Both motor and cognitive functions will be assessed after injury, after which mice will be euthanized for analysis of hippocampal neurodegeneration and cortical tissue damage to assess the neuroprotective actions of hCAST overexpression. The expectation is that hCAST transgenic mice will have reduced posttraumatic calpain proteolytic activity, offering a neuroprotective advantage. Aim 2 establishes an alternative approach to hCAST overexpression through lentiviral vector delivery. After injection of control lentivirus or calpastatin lentivirus into the cortex or hippocampus, mice will be subjected to 1.0mm CCI brain injury or sham treatment and assessed as in Aim 1. Targeting of calpastatin to vulnerable neuronal regions prior to injury should spare affected neurons and reduce behavioral deficits. PUBLIC HEALTH RELEVANCE: Given the scope of traumatic brain injury, it is imperative to understand the mechanisms of neuronal damage and death in order to develop effective treatment strategies. My research aims will not only seek to establish a functional, neuroprotective role for calpastatin in brain trauma but also advance translational efforts for the treatment of brain injury.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Alteration of tau splicing to identify and treat tauopathies
  • 批准号:
    8912294
  • 项目类别:
  • 资助金额:
    $5.88万
  • 财政年份:
    2014
  • 负责人:
    Kathleen Marie Schoch
  • 依托单位:
Calpastatin overexpression as a therapeutic approach to traumatic brain injury
  • 批准号:
    8061915
  • 项目类别:
  • 资助金额:
    $3.14万
  • 财政年份:
    2011
  • 负责人:
    Kathleen Marie Schoch
  • 依托单位:
Calpastatin overexpression as a therapeutic approach to traumatic brain injury
  • 批准号:
    8386581
  • 项目类别:
  • 资助金额:
    $0.92万
  • 财政年份:
    2011
  • 负责人:
    Kathleen Marie Schoch
  • 依托单位:
海外基金